The trial was supposed to begin dosing on 1 March but had been delayed as a precaution due to quality concerns that came to light at one of the company’s suppliers during the manufacture of a batch of Thetanix.
The biotherapeutics firm has now received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the clinical study to be restarted.
4D has also completed its own investigation into the matter but gave no further details.
Thetanix is 4D’s proprietary programme for the treatment of Crohn’s Disease, a chronic bowel disease that causes inflammation and swelling across the lining of the digestive tract.
Shares were down 7.5p, or 0.9%, to 850p.